CA2191733A1 - Procedes d'inhibition des reponses des lymphocytes t specifiques a un antigene - Google Patents

Procedes d'inhibition des reponses des lymphocytes t specifiques a un antigene

Info

Publication number
CA2191733A1
CA2191733A1 CA002191733A CA2191733A CA2191733A1 CA 2191733 A1 CA2191733 A1 CA 2191733A1 CA 002191733 A CA002191733 A CA 002191733A CA 2191733 A CA2191733 A CA 2191733A CA 2191733 A1 CA2191733 A1 CA 2191733A1
Authority
CA
Canada
Prior art keywords
antibody
cell
cells
agent
recipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002191733A
Other languages
English (en)
Inventor
Daniel A. Vallera
Bruce R. Blazar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota System
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2191733A1 publication Critical patent/CA2191733A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Procédés d'inhibition des réponses des lymphocytes T spécifiques à un antigène qui consistent à utiliser un agent qui inhibe un signal de co-stimulation dans les lymphocytes T. Afin d'inhiber les réponses des lymphocytes T spécifiques à un antigène, on utilise de préférence un premier agent qui inhibe un signal de co-stimulation dans le lymphocyte T (par exemple une protéine de fusion CTLA41g) ainsi qu~un deuxième agent qui inhibe une autre fonction du lymphocyte T, telle que l'adhésion du lymphocyte T à une cellule qui présente un antigène dirigié contre les lymphocytes T. Par exemple, pour inhiber l'adhésion d'un lymphocyte T à une cellule présentant un antigène, on peut utiliser un anticorps anti-LFA-1 associé à une protéine de fusion CTLA41g. De plus, on peut également utiliser un autre agent qui inhibe un signal de co-stimulation dans les lymphocytes T, tel qu'un anticorps anti-B7-1 ou un anticorps anti-B7-2, conjointement avec un deuxième agent qui inhibe un signal de prolifération dans le lymphocyte T, par exemple un anticorps du récepteur anti-IL-2. Ces procédés sont particulièrement utiles pour inhiber la réaction du greffon contre l'hôte et le rejet de tissus ou d'organes transplantés.
CA002191733A 1994-06-07 1995-06-07 Procedes d'inhibition des reponses des lymphocytes t specifiques a un antigene Abandoned CA2191733A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25526794A 1994-06-07 1994-06-07
US47269795A 1995-06-06 1995-06-06
US08/472,697 1995-06-06
US08/255,267 1995-06-06

Publications (1)

Publication Number Publication Date
CA2191733A1 true CA2191733A1 (fr) 1995-12-21

Family

ID=26944578

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002191733A Abandoned CA2191733A1 (fr) 1994-06-07 1995-06-07 Procedes d'inhibition des reponses des lymphocytes t specifiques a un antigene

Country Status (5)

Country Link
EP (1) EP0784482A2 (fr)
JP (1) JPH10501815A (fr)
AU (1) AU2701895A (fr)
CA (1) CA2191733A1 (fr)
WO (1) WO1995034320A2 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4158396A (en) * 1994-11-10 1996-06-06 Dana-Farber Cancer Institute Methods for inhibiting graft versus host disease in bone marrow transplantation
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
WO1996034970A1 (fr) * 1995-05-04 1996-11-07 United States Of America, Represented By The Secretary Of The Navy Procedes ameliores de transfection des lymphocytes t
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US5855887A (en) * 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) * 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
ES2203782T3 (es) * 1996-01-17 2004-04-16 Imperial College Innovations Limited Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
IL125928A (en) * 1996-03-20 2002-11-10 Bristol Myers Squibb Co The use of soluble ligands that react with CTLA4, B7, CD40, gp39 and / or CD28 for the preparation of pharmaceutical preparations
US6060054A (en) * 1996-04-10 2000-05-09 National Jewish Medical And Research Center Product for T lymphocyte immunosuppression
ES2133085B1 (es) * 1996-12-30 2000-04-01 Hospital Universitario Virgen Metodo de analisis del rechazo agudo en trasplante ortotopico de higado mediante la determinacion de la intensidad de expresion de las moleculas coestimuladoras (cd28, ctla-4, cd80 y cd86) en la superficie de linfocitos de sangre periferica por citometria de flujo.
US6319906B1 (en) 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7235653B2 (en) 1996-12-31 2007-06-26 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6077833A (en) * 1996-12-31 2000-06-20 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
EP1009432A4 (fr) * 1997-06-11 2004-07-07 Us Navy Composition et procede pour prevenir des rejets de greffe ou d'autres reponses immunitaires non adaptives des lymphocytes t
CA2319448A1 (fr) 1998-02-04 1999-08-12 The General Hospital Corporation Blocage costimulant et chimerisme mixte dans les allotransplantations
US6841347B1 (en) 1998-02-05 2005-01-11 The General Hospital Corporation In vivo construction of DNA libraries
DK1074268T3 (da) 1998-03-17 2008-04-28 Chugai Pharmaceutical Co Ltd IL-6-receptorantagonistantistofholdige forebyggende eller terapeutiske midler mod inflammatoriske tarmsygdomme
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
AU5906099A (en) * 1998-09-04 2000-03-27 Baylor College Of Medicine T cell peptides as therapeutics for immune-related disease
EP1144010B1 (fr) * 1999-01-08 2007-04-18 Wisconsin Alumni Research Foundation Prévention du rejet chronique de greffe par une combinaison d'immunotoxines et de bloqueurs de la costimulation
AU3998800A (en) 1999-02-12 2000-08-29 Genetics Institute, Llc Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
US6541608B1 (en) 1999-02-23 2003-04-01 Baylor College Of Medicine T cell receptor Vβ-Dβ-Jβ sequence and methods for its detection
CA2362099C (fr) 1999-02-23 2014-05-13 Baylor College Of Medicine Sequence v.beta.-d.beta.-j.beta. du recepteur de leucocytes t et procedes de sa detection
MXPA01011279A (es) 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2001068134A2 (fr) * 2000-03-14 2001-09-20 Genetics Institute, Inc. Therapies permettant d'ameliorer la survie d'un greffon
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
WO2001095928A2 (fr) * 2000-06-09 2001-12-20 Bristol-Myers Squibb Company Procedes de regulation de reponse immunitaire a mediation cellulaire au moyen du blocage des signaux lymphocytaires et du blocage de l'adhesion induite par l'antigene lfa-1
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
SI1372696T1 (sl) 2000-07-03 2008-12-31 Bristol Myers Squibb Co Metoda za zdravljenje revmatskih bolezni z uporabo topne molekule ctla4
DE60133029T2 (de) 2000-10-25 2009-03-12 Chugai Seiyaku K.K. Mittel zur prävention oder behandlung von psoriasis mit einem il-6-antagonist als wirkstoff
MXPA03010568A (es) 2001-05-23 2005-03-07 Squibb Bristol Myers Co Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles.
US7897582B2 (en) 2003-05-23 2011-03-01 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7960355B2 (en) 2003-05-23 2011-06-14 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of the expression of B7 protein
KR20050082389A (ko) * 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
ATE556134T1 (de) * 2004-03-22 2012-05-15 Osiris Therapeutics Inc Mesenchymstammzellen und verwendungendafür
EP1954311A4 (fr) 2005-12-07 2009-12-23 Medarex Inc Régimes d'escalade de dose d'anticorps ctla-4
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
EP2253644B1 (fr) 2005-12-20 2013-10-16 Bristol-Myers Squibb Company Compositions et procédés pour la production d'une composition
US20070258963A1 (en) 2006-01-13 2007-11-08 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing TNF-alpha receptors
US20120087933A1 (en) 2010-10-08 2012-04-12 Samson Tom Enhanced msc preparations
US20220064311A1 (en) * 2018-12-18 2022-03-03 Catapult Therapeutics B.V. The use of anti-CCR7 mabs for the prevention or treatment of graft-versus-host disease (GvHD)
WO2020172391A1 (fr) * 2019-02-22 2020-08-27 The Children's Medical Center Méthodes et compositions se rapportant au traitement de la gvhd
JP7449390B2 (ja) 2020-01-24 2024-03-13 ファイザー・インク 抗ｅ－セレクチン抗体、組成物および使用の方法
CN117222667A (zh) * 2021-03-16 2023-12-12 Jn生物科学有限责任公司 用于治疗免疫失调的双功能分子

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7405294A (en) * 1993-07-26 1995-02-20 Dana-Farber Cancer Institute B7-2: ctl a4/cd 28 counter receptor

Also Published As

Publication number Publication date
AU2701895A (en) 1996-01-05
WO1995034320A2 (fr) 1995-12-21
WO1995034320A3 (fr) 1996-01-18
JPH10501815A (ja) 1998-02-17
EP0784482A2 (fr) 1997-07-23

Similar Documents

Publication Publication Date Title
CA2191733A1 (fr) Procedes d'inhibition des reponses des lymphocytes t specifiques a un antigene
US20230302052A1 (en) Methods for treating chronic lymphocytic leukemia (cll)
US11667723B2 (en) Lymphocytes-antigen presenting cells co-stimulators and uses thereof
DE69713336T2 (de) Verfahren zur Herstellung von aktivierten markierten tumorspezifischen T-Zellen und deren Verwendung in der Behandlung von Tumoren
DE69519513T2 (de) Verfahren zur modulation von "t-zell-anergy"
ES2354156T3 (es) Activación y expansión de células t.
JP6879910B2 (ja) Ｃａｒｔ細胞における遺伝子発現の改変およびその使用
DE69533984T2 (de) Verfahren zur anregung von t-zelltoleranz gegen ein gewebe- oder organtransplantat
Haspot et al. Anti‐CD28 Antibody‐Induced Kidney Allograft Tolerance Related to Tryptophan Degradation and TCR− Class II− B7+ Regulatory Cells
US20080305092A1 (en) Methods of treating autoimmune disease via CTLA-4IG
TW200403340A (en) Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
DE69731836T2 (de) Induzierung von t zell toleranz unter verwendung eines löslichen moleküls, dass gleichzeitig zwei kostimulierungswege blockieren kann
JP2006514024A (ja) Ｎｋ細胞の増殖に対する効果を有する医薬組成物及びそれを使用する方法
Thomson et al. IN VITRO PROPAGATION AND HOMING OF LIVER-DERIVED DENDRITIC CELL PROGENITORS TO LYMPHOID TISSUES OF ALLOGENEIC RECIPIENTS: Implications for the Establishment and Maintenance of Donor Cell Chimerism Following Liver Transplantation: 1, 2
DE69535713T2 (de) Verfahren zur modulierung von t-zellreaktionen durch manipulation einer gemeinsamen zytokinrezeptor-gammakette
WO2006110582A1 (fr) Compositions et methodes de traitement des brulures et de la sepsie
WO1996014865A1 (fr) Procedes d'inhibition de la reaction du greffon contre l'hote lors d'une greffe de moelle osseuse
JP2003502387A (ja) プライミングされた抗原特異的ｔ細胞またはｂ細胞を用いる自己養子免疫療法
Shiohara et al. Differential expression of lymphocyte function-associated antigen 1 (LFA-1) on epidermotropic and non-epidermotropic T-cell clones
AU779289B2 (en) Methods for restoring or enhancing T-cell immune surveillance following naturally or artifically induced immunosuppression
AU748561B2 (en) Methods for inhibiting antigen specific T cell responses
US20020182727A1 (en) Methods for selectively modulating a Th2-type response within a population of activated CD4+ T cells
WO2004087876A2 (fr) Utilisation de globules rouges pour faciliter l'activation cellulaire
US20250242045A1 (en) Beads for targted signla delivery
Tan The role of 4-1BB costimulation in the regulation of T cell responses

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead